© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Colorectal Cancer
Targeting KRAS in Colorectal Cancer Is an Ongoing Medical Challenge
October 01, 2020
Due to the high prevalence of KRAS-mutant colorectal cancer and the fact that many different KRAS variants are found in these tumors, developing treatment for patients with KRAS-mutant colorectal cancer is an area of unmet medical need
Improvements Seen in Health-Related QoL With First Line Pembrolizumab for DNA Repair-Deficient Metastatic CRC
September 19, 2020
The health-related quality of life had clinically meaningful improvements with pembrolizumab as a first-line therapy for patients with microsatellite instability-high and/or mismatch repair-deficient metastatic colorectal cancer versus standard-of-care chemotherapy, according to new data presented at the ESMO Virtual Congress 2020.
Eflornithine Plus Sulindac Has Limited Impact on Disease Progression in Familial Polyposis
September 17, 2020
The incidence of disease progression in patients with familial adenomatous polyposis was not significantly lower when patients were treated with eflornithine plus sulindac compared with either drug alone.
Black Patients Experience Lower OS With CRC Liver Metastases Than Others
September 12, 2020
Compared to other racial and ethnic groups, Black patients were the least likely to receive chemotherapy or surgical resection for colorectal liver metastases and experienced worse survival, according to a published research paper.
Liquid Biopsy Assay May Be Predictive of Survival With Rechallenging Anti-EGFR Treatment in mCRC
September 01, 2020
RAS status detected in circulating tumor DNA was associated significantly with clinical outcomes when patients with metastatic colorectal cancer were rechallenged with anti-EGFR monoclonal antibody therapy of either cetuximab or panitumumab, according to findings from a clinical study evaluating RAS mutational status in ctDNA using the OncoBEAM RAS CRC test kit in 2 Japanese multicenter, prospective studies.
The Science Leading to Robust Responses in MSI-High Mismatch Repair Deficient mCRC in CheckMate 142
July 23, 2020
In an interview with Targeted Oncology, Heinz-Josef Lenz, MD, PhD, discussed the history of immune checkpoint inhibition in the metastatic colorectal cancer treatment paradigm.
Analyzing the Importance of Biomarker Testing and MSI Status in mCRC
July 20, 2020
Heinz-Josef Lenz, MD, discusses the significance of conducting biomarker testing in patients with metastatic colorectal cancer in accordance with the results of the phase 2 CheckMate-142 trial.
FDA Approves Frontline Pembrolizumab for MSI-H/dMMR CRC
June 29, 2020
"Patients with unresectable or metastatic MSI-H colorectal cancer have historically faced poor outcomes, and until today, chemotherapy-containing regimens were the only FDA-approved first-line treatment options."
Trastuzumab Deruxtecan Demonstrates Efficacy for mCRC in DESTINY-CRC01
June 29, 2020
Salvatore Siena, MD, discusses the efficacy of the phase 2 DESTINY-CRC01 trial of trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer who have progressed on 2 or more treatments in this setting.
NDA Seeks Accelerated Approval of CPP-1X/sul for Familial Adenomatous Polyposis
June 29, 2020
A New Drug Application was submitted to the FDA seeking accelerated approval of eflornithine in combination with sulindac for the treatment of adult patients with familial adenomatous polyposis.